Narrative review examines coronary risk and vascular effects of bisphosphonates, denosumab, and romosozumab in osteoporosis
Osteoporosis drugs show no clear heart risk or benefit
This narrative review evaluates the cardiovascular safety profile of anti-osteoporosis therapies including bisphosphonates, denosumab, and r…
Common osteoporosis drugs don't have a clear effect on heart health, but one newer drug still raises safety questions.
Case report review of VMAT, utidelone, and denosumab in a breast cancer patient with clivus metastasis
Rare Breast Cancer Skull Case Achieves Long-Term Remission With New Plan
This case report review describes a single breast cancer patient with clivus metastasis treated with volumetric modulated arc therapy (VMAT)…
A rare case of breast cancer spreading to the skull shows long-term remission using a specific drug and radiation plan.
Antiresorptive and Anabolic Agents Improve Bone Microarchitecture in Postmenopausal Women With Type 2 Diabetes: Pilot RCT.
Diabetes Weakens Bones: One Drug Builds Them Back
This pilot randomized controlled trial evaluated antiresorptive and anabolic agents in 129 postmenopausal women with Type 2 Diabetes. Teripa…
Building new bone tissue with a specific daily shot works better than just protecting existing bone for women with diabetes.
Meta-analysis shows perioperative denosumab increases local recurrence in giant cell tumor patients.
A Common Bone Tumor Drug May Raise the Risk of Cancer Coming Back
This meta-analysis evaluated perioperative denosumab in 1,551 patients undergoing surgical management of giant cell tumor. The authors synth…
Taking a common bone tumor drug before and after surgery nearly tripled the chance of the tumor growing back in a new analysis of 1,551 pati…
Review Article Examines Bisphosphonates and Denosumab for Multiple Myeloma Associated Bone Disease
Bone Pain in Cancer: New Options, Real Risks
This review article examines the use of bisphosphonates and denosumab in patients with multiple myeloma. The authors synthesize current know…
New drugs target bone breakdown in multiple myeloma without kidney damage, offering hope for patients with weak bones and severe pain.
In male osteoporosis, anabolic therapies improved lumbar spine and hip BMD more than antiresorptives at 12 months.
Men Get Osteoporosis Too — and Now We Know Which Drugs Win
This Bayesian network meta-analysis evaluated antiresorptive and anabolic pharmacological interventions in men with osteoporosis. Across 18 …
A new analysis of 18 clinical trials finds that bone-building drugs may outperform bone-preserving drugs for men with osteoporosis, especial…
Denosumab showed no effect on periprosthetic bone density five years after uncemented total hip arthroplasty.
Denosumab showed no benefit for bone density five years after hip replacement surgery.
This secondary exploratory analysis of a phase-2 randomized controlled trial evaluated denosumab in 54 non-osteoporotic patients undergoing …
Five years after hip surgery, bone density declined for everyone regardless of whether patients took the drug denosumab or a placebo.